These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1491342)

  • 21. Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.
    Paton DM
    Drugs Today (Barc); 2022 Feb; 58(2):77-84. PubMed ID: 35188142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation and structure elucidation of the major photodegradation products of loteprednol etabonate.
    Shirasaki Y; Inada K; Inoue J; Nakamura M
    Steroids; 2004 Jan; 69(1):23-34. PubMed ID: 14715374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
    Lyseng-Williamson KA
    Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in intraocular pressure during long-term use of loteprednol etabonate.
    Novack GD; Howes J; Crockett RS; Sherwood MB
    J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of simultaneous quantification method of loteprednol etabonate (LE) and its acidic metabolites, and analysis of LE metabolism in rat.
    Samir A; Kage A; Ohura K; Imai T
    Xenobiotica; 2019 May; 49(5):569-576. PubMed ID: 29781759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH; Howes J
    Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
    Noble S; Goa KL
    BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.
    Wu WM; Bodor ET; Howes J; Bodor N
    Pharmazie; 2012 May; 67(5):406-10. PubMed ID: 22764572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
    Schopf L; Enlow E; Popov A; Bourassa J; Chen H
    Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate.
    Soliman OAE; Mohamed EAM; El-Dahan MS; Khatera NAA
    AAPS PharmSciTech; 2017 May; 18(4):1228-1241. PubMed ID: 27469220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
    Bodor N; Bodor N; Wu WM
    Curr Eye Res; 1992 Jun; 11(6):525-30. PubMed ID: 1505197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
    Kang C; Keam SJ; Shirley M; Syed YY
    Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation.
    Waterbury LD; Flach AJ
    J Ocul Pharmacol Ther; 2006 Jun; 22(3):155-9. PubMed ID: 16808675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loteprednol etabonate, a new soft steroid is effective in a rabbit acute experimental model for arthritis.
    Buris LF; Bodor N; Buris L
    Pharmazie; 1999 Jan; 54(1):58-61. PubMed ID: 9987798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK; Roel L; Siou-Mermet R; Erb T
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemistry of loteprednol etabonate and related steroids. II. Reactions at ring C and NMR structural studies of the resulting compounds.
    Rachwal S; Druzgala P; Liu ZZ; Vlasak J; Brewster ME; Pop E
    Steroids; 1998 Apr; 63(4):193-201. PubMed ID: 9589553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural studies of loteprednol etabonate and other analogs of prednisolone using NMR techniques.
    Rachwal S; Pop E; Brewster ME
    Steroids; 1996 Sep; 61(9):524-30. PubMed ID: 8883218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways.
    Szelenyi I; Hochhaus G; Heer S; Kusters S; Marx D; Poppe H; Engel J
    Drugs Today (Barc); 2000 May; 36(5):313-20. PubMed ID: 12861354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loteprednol etabonate. Alrex, Lotemax, Loteprednol, Loterox.
    Drugs R D; 2002; 3(3):154-7. PubMed ID: 12099159
    [No Abstract]   [Full Text] [Related]  

  • 40. Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol.
    Hermann R; Locher M; Siebert-Weigel M; LaVallee N; Derendorf H; Hochhaus G
    J Clin Pharmacol; 2004 May; 44(5):510-9. PubMed ID: 15102872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.